CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹41,595 Cr | ₹36,742 Cr | ₹32,130 Cr | ₹29,007 Cr | ₹26,652 Cr |
What is the latest Total Liabilities ratio of CIPLA ?
| Year | Total Liabilities |
|---|---|
| Mar2026 | ₹41,595 Cr |
| Mar2025 | ₹36,742 Cr |
| Mar2024 | ₹32,130 Cr |
| Mar2023 | ₹29,007 Cr |
| Mar2022 | ₹26,652 Cr |
How is Total Liabilities of CIPLA Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹41,595 Cr | 13.21 | |
| Mar2025 | ₹36,742 Cr | 14.35 | |
| Mar2024 | ₹32,130 Cr | 10.77 | |
| Mar2023 | ₹29,007 Cr | 8.83 | |
| Mar2022 | ₹26,652 Cr | - | |
Compare Total Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹108,501.0 Cr | -2.9% | -3.3% | -10.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹427,861.0 Cr | -3.2% | -5.4% | 12% | Stock Analytics | |
| DIVIS LABORATORIES | ₹254,319.0 Cr | 0.7% | 3.2% | 61.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹179,153.0 Cr | -2.8% | -3% | 32.6% | Stock Analytics | |
| MANKIND PHARMA | ₹103,049.0 Cr | -2.4% | 6% | 0.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,362.0 Cr | -3.3% | 4.7% | -2.2% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -2.9% |
-3.3% |
-10.4% |
| SENSEX | -2.1% |
-5.9% |
-10.8% |
You may also like the below Video Courses